Table 4. Serial Determinations of i-DPD... | American Society of Hematology

Table 4.

Serial Determinations of i-DPD in Patients With Progressive Disease

Patient No.	Initial State of Disease	Baseline	Baseline Monoclonal Protein	Baseline Percentage of Plasma Cells	Evolved State of Disease	Follow-up i-DPD	Follow-up Monoclonal Protein	Follow-up Percentage of Plasma Cells	Time Between Baseline and Follow-up Examination
		i-DPD	(g/L)			(μmol/mol)	(g/L)		(mo)
		(μmol/mol)
A	MGUS	6.1	19.55	5%	Stage I MM	4.0	24.33	30%	19
B	MGUS	4.9	27.95	5%	Stage I MM^4-151	4.1	35.44	20%	20
C	MGUS	5.36	28.88	5%	Stage I MM^4-151	12.0	38.88	ND	31
D^4-150	Stage II MM	7.6	45.12	70%	Stage III MM^‡	11.96	63.50	ND	7

Patient No.	Initial State of Disease	Baseline	Baseline Monoclonal Protein	Baseline Percentage of Plasma Cells	Evolved State of Disease	Follow-up i-DPD	Follow-up Monoclonal Protein	Follow-up Percentage of Plasma Cells	Time Between Baseline and Follow-up Examination
		i-DPD	(g/L)			(μmol/mol)	(g/L)		(mo)
		(μmol/mol)
A	MGUS	6.1	19.55	5%	Stage I MM	4.0	24.33	30%	19
B	MGUS	4.9	27.95	5%	Stage I MM^4-151	4.1	35.44	20%	20
C	MGUS	5.36	28.88	5%	Stage I MM^4-151	12.0	38.88	ND	31
D^4-150	Stage II MM	7.6	45.12	70%	Stage III MM^‡	11.96	63.50	ND	7

Because of the high sensitivity of i-DPD in identifying patients with MM and the close correlations between h-PYD, h-DPD, and i-DPD, only i-DPD levels were determined in follow-up urine samples.

F4-150

Patient refused cytostatic treatment.

F4-151

The criterion for the transition of MGUS into stage I MM was a newly diagnosed solitary osteolysis on plain x-ray examination.

‡

The criterion for the transition of stage II MM into III MM was the first radiographic evidence of multiple lytic bone lesions.

View Large

This Feature Is Available To Subscribers Only